CSIMarket Company Name, Ticker, Customers, else..
 
Achieve Life Sciences Inc   (NASDAQ: ACHV)
 
Price: $7.1950 $-0.09 -1.168%
Day's High: $7.440000057220459 Week Perf: -15.25 %
Day's Low: $ 7.16 30 Day Perf: 7.55 %
Volume (M): 213,750 52 Wk High: $ 8.64
Volume (M$): $ 0 52 Wk Avg: $4.95
Open: $7.38 52 Wk Low: $2.62



 Market Capitalization (Millions $) 673
 Shares Outstanding (Millions) 94
 Employees 28
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) -24
 Capital Exp. (TTM) (Millions $) 0

Business Description


Achieve Life Sciences Inc is a pharmaceutical company focused on developing and commercializing treatments for nicotine addiction. The company's lead product candidate is cytisine, a plant-based alkaloid that has been used for smoking cessation in Eastern Europe for several decades. Achieve Life Sciences aims to leverage the established efficacy and safety profile of cytisine to provide an effective and affordable treatment option for smokers looking to quit. The company is actively conducting clinical trials to evaluate the potential of cytisine as a smoking cessation therapy.


   Company Address: 1040 West Georgia Street Vancouver 0 BC
   Company Phone Number: 210-2217   Stock Exchange / Ticker: NASDAQ ACHV


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TVRD        2.97% 
• View Complete Report
   



Product Service News

Achieve Life Sciences Receives FDA Commissioners National Priority Voucher for Cytisinicline for Treatment of Nicoti...

Published Mon, Oct 20 2025 11:06 AM UTC

Breakthrough in Smoking Cessation: Achieve Life Sciences Secures FDA s National Priority Voucher Seattle, WA - October 2023 - In a landmark development, Achieve Life Sciences has been granted the FDA Commissioner s National Priority Voucher for cytisinicline, highlighting it as a pioneering treatment for nicotine dependence, specifically targeting e-cigarette or vaping ces...
Clinical Study

Bridging the Gap Cytisinicline as an Innovative Approach to Smoking Cessation in COPD Patients

Published Mon, Sep 22 2025 12:46 PM UTC

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality, significantly affecting the lives of millions of Americans. Smoking is the primary risk factor for developing COPD, yet many patients struggle to quit. Innovative therapeutic interventions are crucial to support this vulnerable population. Recent data published by Achieve Life Science...
Partnership

Achieve Life Sciences and Omnicom Join Forces for Breakthrough Nicotine Dependence Treatment Launch,

Published Fri, Jun 27 2025 11:30 AM UTC

Achieve Life Sciences Partners with Omnicom for Innovative Launch of New Nicotine Dependence Treatment Achieve Life Sciences, a prominent company specializing in the development of therapies for nicotine addiction, unveiled a strategic partnership with Omnicom, a leading global marketing and communications conglomerate. The collaboration represents a significant step forward...
Clinical Study

Promising Advances in Smoking Cessation Cytisiniclines Role Amid Market Challenges

Published Mon, Apr 21 2025 3:51 PM UTC

In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in JAMA Internal Medicine, highlight the drug s ability to significantly increase quit rates and reduce nicotine cravings among participants when compared to a pl...
Management Changes

Achieve Life Sciences Strengthens Leadership and Progresses Toward Smoking Cessation Breakthrough with Cytisinicline

Published Wed, Oct 16 2024 12:00 PM UTC

In a dynamic move poised to bolster its commercial strategy, Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company renowned for its innovative approach to nicotine dependence treatment, has announced the promotion of Ms. Jaime Xinos to the role of Chief Commercial Officer, effective immediately. This strategic decision comes against the backdrop of ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.65
Working Capital Ratio 1.65
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.61 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.49 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,072,857
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.